Ascendiant Capital maintained its Buy rating for Outlook Therapeutics on June 11, 2026. The firm increased its price target to $10.00 from $6.00. This adjustment represents a 66.67% increase in the projected valuation.
The optimism follows the recent marketing authorization of ONS-5010 in the European Union and United Kingdom. ONS-5010 is an antibody designed to treat wet age-related macular degeneration and other ophthalmic conditions. Analysts expect significant upside as the company advances through further clinical trials and regulatory milestones.